SCIENCE@home

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

M. Karoui,C. Gallois,G. Piessen,J. Legoux,E. Barbier,C. de Chaisemartin,C. Lécaille,O. Bouché,H. Ammarguellat,Francesco Brunetti,M. Prudhomme,J. Regimbeau,O. Glehen,A. Lièvre,G. Portier,J. Hartwig,G. Goujon,B. Romain,C. Lepage,J. Taieb,N. Ainseba,L. Alcaraz,F. Audemar,J. Bachet,A. Bardier,I. Baumgaertner,A. Luciani,T. Bège,M. Ben Abdelghani,V. Bourgeois,C. Brigand,C. Couteau,C. Champetier,M. Chauvenet,P. Debourdeau,S. Deguelte,F. Poizat,A. Sarran,G. Deplanque,D. Olivier,M. Duluc,J. Faucheron,Y. François,M. Freddy,M. Gasmi,J. Gornet,M. Gualtierotti,L. Lacaze,J. Lagasse,C. Lepère,J. Loriau,E. Malaurie,S. Manfredi,F. Mauvais,B. Meunier,L. Mineur,S. N’Guyen,S. Obled,A. Oden Gangloff,J. Ollier,A. Pelletier,D. Père Verge,F. Peschaud,D. Pezet,M. Ramdani,P. Ries‐guye,P. Rougier,E. Rullier,C. Sabbagh,A. Saudemont,J. Seitz,I. Sobhani,W. Tessier,D. Tougeron

Published 2021 in Colorectal Disease

ABSTRACT

Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3‐year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-30 of 30 references · Page 1 of 1

CITED BY

Showing 1-42 of 42 citing papers · Page 1 of 1